We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




European Approval Expands Liquid Biopsy Use in Advanced Breast Cancer Testing

By LabMedica International staff writers
Posted on 12 Oct 2026

Estrogen receptor-positive (ER+), HER2-negative advanced breast cancer may require molecular testing to guide treatment selection, with blood-based assays offering a way to identify tumor mutations that can inform therapy decisions. More...

Supporting this approach, a newly approved liquid biopsy test now provides companion diagnostic testing in Europe for a next-generation oral selective estrogen receptor degrader.

Guardant Health’s Guardant360 CDx has received CE marking under Europe’s In Vitro Diagnostic Medical Devices Regulation (IVDR) as a companion diagnostic (CDx) for AstraZeneca’s ETCAMAH (camizestrant). The test is intended to identify patients with ER-positive, HER2-negative locally advanced or metastatic breast cancer who may benefit from ETCAMAH, a next-generation oral selective estrogen receptor degrader (SERD) and complete ER antagonist. Clinicians can use Guardant360 CDx to test for ESR1 mutations in tumors through a simple blood draw ahead of disease progression.

The company notes that Guardant360 CDx is the first U.S. Food and Drug Administration (FDA)-approved liquid biopsy for comprehensive genomic profiling. The assay detects multiple genomic alterations across solid tumors and is approved as a companion diagnostic for selected therapies in non-small cell lung cancer, breast cancer, and colorectal cancer. The latest European approval further expands its regulatory use as a companion diagnostic for ETCAMAH, following previous approvals for the therapy in the United States and Japan.

The European CE marking represents the third CDx approval for ETCAMAH. It also marks the 31st CDx approval for Guardant Health. The approval expands the platform’s reach and adds to its clinical utility in oncology testing.

“Guardant360 CDx offers molecular insights that can support informed treatment decisions for patients with advanced breast cancer, addressing the disease before it gets out of control. What is even more exciting is that we see tremendous potential for this type of testing protocol to transform the treatment of other cancer types to change the future of oncology,” said Helmy Eltoukhy, Guardant Health chairman and co-CEO.

Related Links
Guardant Health


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Slide Scanner System
NanoZoomer S540MD
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Measuring six variants from one sample may improve research efficiency and support clinical trials of amyloid biology in Alzheimer’s disease and related conditions (Image Credit: Adobe Stock)

Plasma Assay Measures Six Amyloid Beta Peptides for Alzheimer’s Treatment Research

Alzheimer’s disease research and related neurological studies often require tools that can characterize brain amyloid pathology and amyloid beta biology. Blood-based biomarker assays may help researchers... Read more

Molecular Diagnostics

view channel
Image: A new study links broad genomic sequencing before first-line therapy to longer survival, supporting its role in treatment decisions (Image Credit: Shutterstock)

Study Supports Broad Genomic Profiling Before First-Line Lung Cancer Treatment

Biomarker testing plays a critical role in advanced non-small cell lung cancer by identifying patients who may benefit from targeted therapies. However, testing only one or two genes can miss actionable... Read more

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.